Loading...
•
Sep 30, 2020
Heron Therapeutics Q3 2020 Earnings Report
Heron Therapeutics reported a net loss of $58.2 million and CINV franchise net product sales of $20.0 million.
Key Takeaways
Heron Therapeutics announced financial results for Q3 2020, with a net loss of $58.2 million and CINV franchise net product sales of $20.0 million. The company is focused on resubmitting the New Drug Application for HTX-011 in the U.S. and saw the authorization of ZYNRELEF in the EU.
ZYNRELEF received European Commission Authorization for postoperative pain treatment.
A successful FDA Type A meeting was held to discuss HTX-011 for postoperative pain management, with plans to resubmit the New Drug Application in Q4 2020.
CINV franchise net product sales were $20.0 million for the quarter.
2020 net product sales guidance for the CINV franchise was increased to $85 million.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.com Forward Guidance
Heron anticipates a decrease in new diagnoses and chemotherapy patient starts because of the ongoing COVID-19 pandemic (COVID-19), the Company has increased its 2020 guidance for net product sales for the CINV franchise from a range of $70 million to $80 million to net product sales of $85 million.